Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 42

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 42
---
 market; |

| ● | We                                                                                                                                             
 rely on relationships with third-party contract manufacturers and raw material suppliers, which limits our ability to control the availability 
 of, and manufacturing costs for, our product candidates;                                                                                       |

| ● | Our                                                                                                                                           
 future growth depends on our ability to successfully commercialize Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention 
 indications, Celgosivir and our other product candidates, and we can provide no assurance that we will successfully commercialize Arakoda,    
 Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications, Celgosivir and other product candidates;                       |

| ● | Health                                                                   
 care reform measures could materially and adversely affect our business; |

| ● | Our                                                                                                                                           
 competitors may be better positioned in the marketplace and thereby may be more successful than us at developing, manufacturing and marketing 
 approved products;                                                                                                                            |

| ● | We                                                                                                                                   
 compete in an industry characterized by extensive research and development efforts and rapid technological progress. New discoveries 
 or commercial developments by our competitors could render our potential products obsolete or non-competitive;                       |

| ● | We                                                                                                                                         
 would be subject to applicable regulatory approval requirements of the foreign countries in which we market our products, which are costly 
 and may prevent or delay us from marketing our products in those countries;                                                                |

| ● | Defending                                                                                                                              
 against claims relating to improper handling, storage or disposal of hazardous chemicals, radioactive or biological materials could be 
 time consuming and expensive;                                                                                                          |

22

| ● | Geopolitical                                                                                                                            
 conditions, including direct or indirect acts of war or terrorism could have an adverse effect on our operations and financial results; |

| ● | If                                                                                                                                      
 product liability lawsuits are successfully brought against us, then we will incur substantial liabilities and may be required to limit 
 commercialization of Arakoda, Celgosivir or other product candidates;                                                                   |

| ● | Our                                                                                                                       
 intellectual property rights may not preclude competitors from developing competing products and our business may suffer; |

| ● | If                                                                                                                                    
 the manufacture, use or sale of our products infringe on the intellectual property rights of others, we could face costly litigation, 
 which could cause us to pay substantial damages or licensing fees and limit our ability to sell some or all of our products;          |

| ● | We                                                                                
 may not be able to protect our intellectual property rights throughout the world; |

| ●